AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA

The U.S. Food and Drug Administration said on Friday it had approved Daiichi Sankyo Co Ltd and AstraZeneca Plc's drug to treat an advanced form of breast cancer, three months ahead of schedule.